Featured Research

from universities, journals, and other organizations

Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer

Date:
April 1, 2009
Source:
Journal of the National Cancer Institute
Summary:
Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil alone, according to data from a randomized controlled trial.

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.

Related Articles


Patients with locally advanced larynx and hypopharynx cancer are treated frequently with PF chemotherapy followed by radiation as an alternative to surgical removal of the larynx. Recent trials have suggested that adding docetaxel to PF might further improve patient outcomes.

To test this possibility, Gilles Calais, M.D., of the Centre Hospitalier Régional et Universitaire de Tours in France, and colleagues enrolled 213 patients with advanced larynx and hypopharynx cancer in a randomized controlled trial. Patients received induction chemotherapy with either TPF or PF. Those who responded to chemotherapy underwent subsequent radiation therapy, while those who did not respond were treated with surgery.

With a median follow-up time of 3 years, the estimated larynx preservation rate was 70.3 percent in the TPF-treated patients and 57.5 percent in the PF-treated patients. Overall, 80.0 percent of patients in the TPF group responded to therapy, compared with 59.2 percent in the PF group. Patients treated with TPF had more severe infections than those treated with PF.

The authors conclude that the treatment regimen with docetaxel was superior for patients with locally advanced cancers of the larynx and hypopharynx and that more of these patients could avoid total laryngectomy. However, they caution that "Because we proposed treatment to a select popula¬tion of patients with only larynx and hypopharynx cancer and this trial was especially designed for organ preservation, we cannot gen¬eralize the findings to all locally advanced head and neck cancers."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yoann Pointreau, Pascal Garaud, Sophie Chapet, Christian Sire, Claude Tuchais, Jacques Tortochaux, Sandrine Faivre, Stephane Guerrif, Marc Alfonsi, and Gilles Calais. Randomized Trial of Induction Chemotherapy with Cisplatin and 5-fluorouracil with or Without Docetaxel for Larynx Preservation. J Natl Cancer Inst, 2009; 101: 498-506 DOI: 10.1093/jnci/djp007

Cite This Page:

Journal of the National Cancer Institute. "Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer." ScienceDaily. ScienceDaily, 1 April 2009. <www.sciencedaily.com/releases/2009/03/090324171428.htm>.
Journal of the National Cancer Institute. (2009, April 1). Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2009/03/090324171428.htm
Journal of the National Cancer Institute. "Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/03/090324171428.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins